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While survival rates for localized melanoma are above 98%, metastatic melanoma 
proves to be an extraordinarily dreadful disease because of its notoriously poor prognosis 
resulting in less than 15% survival within 5 years. This is due to the fact that the disease 
is highly resistant to standard cancer therapies. With approximately 40% of melanoma 
patients progressing to brain metastasis, a greater understanding of the pathways 
mediating melanoma cell invasion into the brain must be achieved. In this study, a 
potentially key target often deregulated in melanoma and other cancers, Cyclin-
Dependent Kinase 5 (CDK5), will be interrogated for its implications in metastatic 
melanoma cell invasion into the brain. Despite the observed deregulation of CDK5 in 
various cancers as well as human metastatic melanoma cell lines, there is currently 
minimal effort in defining its role in brain metastatic melanoma. This study approaches 
this problem in an innovative way by exploring Neurotrophin Receptors (NTR) signaling 
pathways involving CDK5. Specifically, activated Neurotrophin Receptors induce EGR-
1, thus transcribing p35 and activating its obligate partner CDK5. Considering CDK5 is 
implicated in a variety of cellular processes such as survival and invasion, this pathway 
supports our central hypotheses that activation of CDK5 through Neurotrophin (NT) 
signaling is vital in melanoma cell invasion into the brain. In order to test this hypotheses, 
a transwell invasion assay utilizing human melanoma cells was used in order to mimic 
melanoma metastasis into a brain micro-environment in vitro. In order to implicate 
CDK5 in this study, neurotrophin induced invasion of human metastatic melanoma cells 
with wild-type expression of CDK5 were compared to cells with drug inhibited CDK5 as 
well as lentivirally transduced CDK5 knockout cells. Upon NT stimulation, metastatic 
melanoma cells containing active CDK5/p35 demonstrated a higher propensity to invade 
into the brain micro-environment. Moreover, simultaneous stimulation of metastatic 
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melanoma cells by multiple members of the neurotrophin family were shown to 
synergistically enhance invasion ability into a brain micro-environment when compared 
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Introduction 
 In order to understand the purpose and data generated from this study, various 
pieces of background information must be clearly laid out. In general, this introductory 
section briefly explains the current treatment options for patients with brain metastatic 
melanoma (BMM). From here, the potentially therapeutic target named Cyclin-
Dependent Kinase 5 (CDK5) will be described with regards to its role in metastatic 
melanoma that is supported by existing research. The next part of this introductory 
section details a family of proteins called neurotrophins that existing research shows may 
have a role in melanoma brain metastases. Finally, this introductory section will conclude 
by tying CDK5 to neurotrophins in the context of metastatic melanoma in order to set the 
stage for the experiments that compose this study.  
Current Treatments for Patients with Brain Metastatic Melanoma 
 Over the past 50 years, the annual mortality due to melanoma in humans has 
increased more than any other form of cancer1. While survival rates for localized 
melanoma are above 98%, metastatic melanoma proves to be an extraordinarily dreadful 
disease because of its notoriously poor prognosis at less than 15% survival over 5 years 
in addition to the tendency of this disease to resist standard cancer therapy regiments2. 
One common site of metastasis observed in human melanoma is the brain, with 
approximately 40% melanoma patients progressing to brain metastatic melanoma 
(BMM)3. In order for brain metastasis to occur, melanoma cells must travel from the 
primary tumor site, migrate to the brain, invade across the blood brain barrier, and 
survive long enough to induce angiogenesis that will allow tumor cell proliferation to 
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occur in the brain tissue4. Only 0.01%-0.03% of melanoma cells will metastasize to any 
target organ, thus illustrating that a small proportion of cells can lead to immense 
problems within the body5-9. Currently, the primary treatment option for BMM patients is 
surgical resection, which carries the risk of damaging healthy brain tissue and oftentimes 
does not improve patient prognosis to a significant degree4. Furthermore, standard cancer 
treatments such as chemotherapy typically yield low response10. Recently, targeted 
therapies involving inhibition of key signaling intermediates in melanoma metastasis 
have shown promising results, but are often hindered due to toxicity4. One example of 
targeted therapies for BMM can be seen through BRAF inhibitors. The BRAF oncogene 
harbors a mutation in roughly 65% of melanoma patients, leading to constitutive 
activation of the MEKERKEGF-1 pathway, and thus upregulation of p35, ultimately 
leading to constitutive activation of CDK5. BRAF pathway inhibitors such as dabrafenib 
and vemurafenib have been tested in a clinical setting with some success. Specifically, 
the BRAF inhibitor dabrafenib showed similar response in patients with and without prior 
treatment, indicating BRAF inhibition as a viable option for coupled treatments. In 
addition, the side effects of dabrafenib were relatively limited and included primarily 
fatigue and nausea.  In this regard, certain BMM cases such as those with extensive extra-
cranial metastasis may qualify for initial BRAF inhibition followed by surgical resection.  
However, an additional limitation for surgical resection is the necessary use of 
corticosteroids following the procedure, possibly leading to the impairment of coupled 
immunotherapeutic treatments. Even following surgical resection, patient prognosis is 
still poor and the procedure carries the potential to damage the brain. However, 
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treatments such as BRAF inhibition that can suppress tumor growth and allow for a more 
successful surgical resection demonstrate a promising avenue to pursue.   
 Whole brain radiotherapy is used to supplement or even replace the 
surgical procedure, although relying on whole brain radiotherapy as the primary 
treatment option is often reserved for cases involving larger tumors (>3cm) or an 
abundance of metastatic sites in the brain (>3)4. If possible, targeted radiotherapy is used, 
limiting the damaging effects to the brain incurred in whole brain radiotherapy.  
 Patients with BMM show poor response to standard chemotherapy due to a 
variety of factors that are not well understood. This may be due to the inability of the 
treatment to penetrate the blood-brain-barrier as well as tumor cell resistance to apoptosis 
via paracrine signaling from astrocytes near the tumor site11-12.  Even those 
chemotherapies that are proven to penetrate the blood-brain-barrier are hampered by low 
response rates and short duration of response. However, chemotherapy coupled with 
whole brain radiotherapy has shown indications of improved patient prognosis.  
 Recently, immunotherapies have been shown to be relatively effective and safe in 
treating human metastatic melanoma. One such example, ipilimumab, functions to 
potentiate anti-tumor response and has been shown to be relatively effective in treating 
asymptomatic cases of BMM. In relation to this, patients with BMM who display higher 
levels of vascular endothelial growth factor (VEGF) in the blood have a poor response to 
the immunotherapy ipilimumab4. This is due to the fact that high levels of VEGF 
promotes angiogenesis and suppresses the anti-tumor response of immune cells, a process 
that is needed in order for tumors in the brain to grow. As a result of this, antiangiogenics 
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have been considered as a potential treatment option for patients with BMM.  However, 
up to one fifth of patients treated with antiangiogenics experience hemorrhaging in 
clinical trials.  
 Overall, it is clear that current treatment options for patients with BMM leave a 
lot to be desired. However, the promise that novel treatments such as those seen with 
BRAF inhibitors demonstrate that downstream effectors in the BRAF pathway may prove 
to be worthwhile therapeutic targets. One such target is CDK5. This kinase has been 
implicated as a relevant target in a variety of cancers, yet has not been established as a 
therapeutic target for patients with BMM.  
Cyclin-Dependent Kinase 5 in the Context of Metastatic Melanoma 
 When CDK5 was first studied, it was believed to be implicated mostly in neuronal 
function and development. However, numerous studies have since shown that this kinase 
is expressed in all tissues and plays a role in an extraordinary amount of disease 
pathologies and cell processes including but not limited to cell cycle, growth, migration 
and invasion. In fact, evidence supports that CDK5 is involved in both tumor 
development as well as metastatic processes. Not surprisingly then, CDK5 has been 
shown to be upregulated in numerous cancers. Specifically to melanoma, one study of 45 
patients revealed an average of over a 21-fold increase in CDK5 expression in the tumor 
tissue 13. To compound this, normal skin and nevus cells show no expression of CDK5, 
showing that melanoma tumor formation accompanies a rise in expression of CDK5 14. 
Melanoma cells have been shown to be responsive to CDK5 inhibition. Specifically, 
mouse models of melanoma have demonstrated reduced tumor growth in cohorts treated 
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with dinaciclib, a small molecule CDK inhibitor, when compared to cohorts not treated 
with a CDK inhibitor 15. However, the utility of CDK5 inhibitors in treating BMM is not 
yet clear.  
Neurotrophins in the Context of Metastatic Melanoma 
Just over 25 years ago, nerve growth factor (NGF) was identified as a factor for 
neuronal survival16. This was the first in a family of survival factors that would go on to 
be classified as neurotrophins. However, not all neuronal populations were responsive to 
NGF, and thus the search for other factors led to the isolation additional members of this 
family of proteins; NGF, brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3), and neurotrophin-4 (NT-4). These four neurotrophins are the only four found in 
mammals. Although neurotrophins are implicate in a variety of processes, this study is 
concerned primarily with the established role of neurotrophins in cell survival and 
differentiation17. These effects are due to pathways activated by the interaction between 
neurotrophins and several different cell-surface receptors that specifically bind one or 
more member in the neurotrophin family. There are two separate classes of these cell-
surface receptors; the Trk family of receptors, which bind with higher affinity and 
specificity, and the p75 neurotrophin family receptor (p75NTR), which binds with low 
affinity and specificity18. While the p75NTR binds all mammalian neurotrophins, the Trk 
family of receptors, which includes TrkA, TrkB, and TrkC) bind only specific 
neurotrophins. Particularly, TrkA binds Nt-3 and NGF, TrkB binds BDNF, NT-3, and 
NT-4, and TrkC binds NT-3.  
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Although the role of neurotrophins was originally studied in the context of 
neuronal populations, neurotrophins also function in a variety of other tissues, namely in 
the skin. Evidence shows that these proteins function both in both an autocrine and 
paracrine manner in the skin, suggesting a probable role in the invasive capacity of 
metastatic melanoma. Not only have studies shown that neurotrophins promote 
melanoma cell survival, but also brain tissue adjacent to brain tumor cells secrete 
neurotrophins. Moreover, neurotrophins also induce cellular production of heperanase in 
melanoma cells, lending to brain invasive capacity19.  
Neurotrophins and CDK5 in Metastatic Melanoma 
 The skin and nervous system share a common neuroectodermal origin, supporting 
the possibility that melanoma has a high propensity to invade the brain because it 
provides a favorable environment for metastatic melanoma cells to thrive. However, the 
role of neurotrophins in metastatic melanoma has been studied relatively little compared 
to other cancers derived from the neural crest, despite the fact that cancers of this origin 
share oncogenic pathways 20, 21.  One such pathway can be seen in Figure 1. This pathway 
demonstrates an interconnection between neurotrophin signaling and CDK5 expression 
mediated by a variety of intermediates. In this way, it can be seen that stimulation of 
metastatic melanoma cells by neurotrophins can lead to increased invasion capacity via 
up-regulation of the obligate activator of CDK5 named p35. The following experiments 
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seek to elucidate this pathway and establish CDK5 as a promising therapeutic target in 
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Methods 
 In order to implicate CDK5 in the melanoma brain metastasis, we planned two 
experiments involving reduction of CDK5 activity in metastatic melanoma cells for use 
in Matrigel transwell assays that mimic a brain micro-environment.  
Experiment 1 
The purpose of the first experiment was to demonstrate that the invasive capacity 
human metastatic melanoma cells into a brain micro-environment is proportional to 
CDK5 activity. In other words, higher CDK5 activity results in a higher propensity for 
invasion into a brain micro-environment. In order to accomplish this aim, a CDK5 
inhibitor known as roscovitine was 
used in various concentrations to 
reduce CDK5 activity. The structure 
of roscovitine, which can be seen in 
figure 2, is a purine analog and thus 
competes for the ATP binding pocket 
on CDK5. By blocking CDK5 from 
binding ATP, the kinase loses its 
phosphorylating ability and is thus inactive. A 
cross-section of a single well in the 24 transwell 
plate that was used for this assay can be seen in figure 3. Each well in the transwell plate 
contains two halves which are separated from one another by a cell permeable Matrigel 
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vitro model of a blood brain barrier. Cells are able 
to permeate this membrane by chemotactically 
migrating through 8 micron pores in the Matrigel 
in response to a chemoattractant contained in the 
bottom half of the transwell. In experiment 1, the 
top half of each well was seeded in serum-free 
RPMI media at a density of 2x105 WM9 cells per 
well with wildtype CDK5 expression (CDK5WT). 
Then, Roscovitine was introduced into the top half 
of the well in various concentrations (0µM, 1µM, 
5µM, and 10µM). At the same time, either neural 
conditioned media (NCM) of neurobasal media 
(NBM) was added to the bottom of each well. NCM is conditioned by primary neuronal 
cells isolated from p0 stage mice. Thus, NCM contains all sorts of molecules, namely a 
host of neurotrophins including NT-3, NT-4, NGF, and BDNF. On the other hand, NBM 
is the essential media for neuronal cell culture and contains no cytokines such as 
neurotrophins. After the WM9 CDK5WT cells were seeded and both the roscovitine and 
either NCM or NBM were added, the transwell plate was set an in incubator and the 
assay was allowed to progress for 17 hours. After this time lapse, any cells that were able 
to migrate across the Matrigel membrane adhered to the bottom of the membrane. This 
allowed for these invaded cells to be fixed and stained, allowing for clear visualization 
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invasion versus an instance of low invasion can be seen in figure 4. After capturing 
images of the invaded 
cells, the number of 
invaded cells was 
quantified by cell 






Similar to the first experiment described above, the second experiment in this 
study utilized a transwell assay mimicking a brain microenvironment in conjunction with 
a unique method of knocking down CDK5 expression. In order to reduce CDK5 
expression, and therefore CDK5 activity, WM9 human metastatic melanoma cells were 
transduced with the pGIPZ lentiviral vector containing CDK5shRNA for gene 
knockdown, GFP for transduction tracking, and a puromycin resistance marker to allow 
for specific selection of successfully transduced cells. In order to accomplish this, 
plasmids from E.Coli expressing CDK5 were isolated via MaxiPrep. Then 293T 
packaging cells were plated at 1x106 cells per 10cm plate. After the 293T cells were 
seeded, a transfection mix including the isolated CDK5 plasmids were added along with 
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produce a viral supernatant containing lentiviral particles with CDK5shRNA, GFP, and 
puromycin resistance markers. After overlaying the transfection mix on the medium of 
each plate containing 293T packaging cells for 40 hours, the viral supernatant was 
collected. 1ml of viral supernatant 
and 3µL of Polybrene were added 
with to each well in a six well plate 
that was seeded with 4x105 WM9 
human metastatic melanoma cells. 
After 40 hours of incubation, the 
WM9 cells were observed for GFP 
expression; an indication of 
successful transduction. Figure 5 
shows a representative image of an instance of high lentiviral transduction efficiency. 
Finally, cells were selected with 
puromycin and the successful 
transduction of CDK5shRNA into the 
WM9 cells was confirmed via western 
blotting.  
Following lentiviral transduction, 
WM9 CDK5shRNA cells were utilized in 
a transwell assay similar to the one 
described in experiment 1. Figure 6 depicts 
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transwell assay used in experiment 2. In this transwell assay, similar methods of 
preparation were used compared to those used in experiment 1. However, the top half of 
each well was seeded with either WM9 CDK5shRNA or WM9 shLuc cells, which 
functions as a control vector. In the bottom half of each well, NCM, NBM, or NBM + 
NGF was added as a chemoattractant. Methods for quantification of invaded cells were 
analogous to those seen in experiment 1.  
  




The results from the transwell assay described previously for experiment 1 can be 
seen in Figure 7.  
The vertical axis represents the number of cells that successfully invaded into the 
brain micro-environment relative to each condition. The highest invasion was seen in the 
case of NCM as a chemoattractant with no roscovitine added, and thus this condition was 
set at 1.0. Increasing concentrations of roscovitine resulted in progressively lower levels 
of invasion. Relative to the no roscovitine condition, treatment with 1µM roscovitine 
resulted in a 12% decrease in invasion, treatment with 5µM roscovitine resulted in a 50% 
decrease in invasion, and treatment with 10µM roscovitine resulted in a 75% decrease in 
invasion. NBM was used as a control and demonstrated 70% lower invasion when 
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Experiment 2 
The results from the lentiviral transduction and subsequent transwell assay 




As can be seen in Figure 8, lentiviral transduction of the WM9 cells with 
CDK5shRNA resulted in a severe decrease in CDK5 expression compared to the control. 
Thus, the WM9 CDK5shRNA cells demonstrated a significantly reduced invasion ability 
in the transwell assay regardless of the chemoattractant used, as can be seen in Figure 9. 
Additionally, the condition in the transwell assay utilizing NCM as a chemoattractant 
showed the highest invasion ability. Notably, conditions utilizing only NBM as a 
chemoattractant showed reduced invasion compared to conditions utilizing NBM + NGF 
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Discussion 
Ultimately, the data generated from both experiments 1 and 2 support our central 
hypotheses that CDK5 is a vital mediator of WM9 metastatic melanoma cell invasion 
into a brain micro-environment in response to neurotrophin stimulation. In experiment 1, 
drug induced inhibition of CDK5 showed significant reduction in the ability of WM9 
cells to invade a brain micro-environment. Thus, this data provides evidence that CDK5 
is a promising therapeutic target for patients with BMM, particularly considering that 
neurotrophins play a significant role in the event of brain metastasis. It is possible that 
roscovitine induced inhibition of CDK5 effects cell viability moreso than invasion 
propensity, however this effect would still be beneficial to patients with BMM if it could 
be targeted specifically to melanoma cells.  
Data generated from experiment 2 provides further evidence that CDK5 is a 
relevant therapeutic target for patients with BMM. If tumor cells could be specifically 
transduced with CDK5shRNA, additional avenues for treatment options for BMM may 
open. On a separate note, the data generated from experiment 2 supports existing research 
that neurotrophins are responsible for melanoma brain metastasis. This notion is derived 
from the fact that the chemoattractant of NBM + NGF resulted roughly twice the invasion 
compared to just NBM as a chemoattractant. Thus, neurotrophins must be at least 
partially responsible for promoting metastatic melanoma cells to invade a brain 
microenvironment. Additionally, this data indicates that neurotrophin induced invasion 
ability is bolstered when multiple types of neurotrophins, such as both NGF and NT-3, 
stimulate the cell. 
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Future studies should seek to further elucidate intermediates in the BRAF 
signaling pathway and their role in brain metastatic melanoma. In this way, additional 
promising therapeutic targets may be revealed. Furthermore, further studies should utilize 
a brain metastatic melanoma model in mice so that the relevance of CDK5 in BMM can 
be explored in vivo, thus taking another step towards bringing new treatment options to 
the clinic for patients with this dreadful disease. 
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